NCT05402852View on ClinicalTrials.gov

Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2023

Conditions
Osteoporosis, Postmenopausal
Interventions
DRUG

EuBone ® capsule

Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.

DRUG

placebo

Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.

Trial Locations (1)

250014

Shandong Provincial Qianfoshan Hospital, Ji'nan

Sponsors
All Listed Sponsors
collaborator

Qianfoshan Hospital

OTHER

collaborator

Chenland Nutritionals lnc.

UNKNOWN

collaborator

Jinan Hetai Pharmaceutical Technology Co., LTD

UNKNOWN

lead

Shandong University

OTHER

NCT05402852 - Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women | Biotech Hunter | Biotech Hunter